In the trial, SD-101 will be administered intratumorally in combination with localized low-dose radiation. The open-label, dose escalation and expansion design of the trial is intended to accelerate
The new laboratory will be used to carry out discovery and research to develop drug candidates that use new linker technologies that couple chemotherapeutic agents and proteins either
Palbociclib selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 to regain cell cycle control and block tumor cell proliferation. Under the new drug application (NDA), the company is
Perampanel is used as an adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. The partnership
The research program is part of a recent grant secured by PATH from the Bill & Melinda Gates Foundation to develop a model for improving the production of
The fixed combination capsule Akynzeo is distributed and marketed by Eisai, under license from Switzerland-based Helsinn Healthcare. Oral palonosetron was approved in 2008 and it prevents nausea and
Drisapersen secured FDA fast track status, making the drug eligible for a rolling review of an NDA and was also granted breakthrough therapy designation in June 2013. Prosensa
Both epilepsy and migraines appear to be triggered by the same coritcal spreading depression (CSD) in the brain, and the difference between the two is the rate of
NPPA is a government regulatory agency that controls the prices of pharmaceutical drugs in India. The company has also received a show cause notice to explain in two
Approved under the tradename Sovaldi in December 2013, Harvoni is a combination of the NS5A inhibitor ledipasvir and the nucleotide analog polymerase inhibitor sofosbuvir. The FDA approval is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.